Fabry Disease Treatment Market is Expected to Reach $3.81 bn by 2027
The Fabry’s Disease Treatment Market was valued at US$ 1.8 billion in the year 2019 and is estimated to reach US$ 3.81 billion by 2027, at a CAGR of 9.83%.
Synonyms of Fabry’s Disease: Alpha-galactosidase A deficiency, Anderson-Fabry disease, Angiokeratoma corporis diffusum, Angiokeratoma diffuse, Ceramide trihexosidase efficiency, GLA deficiency, Hereditary dystopic lipidosis
Fabry’s disease is an X-linked rare metabolic disorder that affects 1 in 40000 to 60000 males, globally. The disease is characterized by GLA gene mutation encoding the gene α-galactosidase A that breaks down the lipid substance globotriaosylceramide. A mutation in the GLA gene disrupts the globotriaosylceramide metabolism leading to the build-up of this compound in the body resulting in complications in skin, kidneys, nervous system and cardiovascular functions. The male population is more prone to the disorder due to the presence of only one X chromosome while the female population has two X chromosomes, of which one can serve as an alternative to the mutated GLA gene. Yet, the female population act as carriers and less prone to develop complications of the disease during the initial stages. But neurological complications, heart failure, high blood pressure, stroke, etc. have been reported to develop gradually. The main symptoms are pain, burning sensation, cloudy vision, excess sweating, improper bowel movements, etc. The disease is diagnosed by measuring α-gal A enzyme in the leukocytes of the patients. In the female, this test can detect only 50% of the carriers. Genetic testing for mutation in the GLA gene confirms Fabry’s disease. In the case of the neonates, the presence of this disease is identified when assessed for improper heart or kidney development.
The primary aim of the treatment is to reduce and relieve the patients of the debilitating pain and to prevent the disease progression. Fabry’s disease cannot be cured but with effective treatment, the damage caused can be curtailed. An intravenous administration of the Agalsidase-β was approved by FDA-approved as an enzyme replacement therapy (ERT) for treating Fabry’s disease in the year 2003. Before which the treatment regimen includes carbamazepine and diphenylhydantoin to reduce pain and the average lifespan of the patients were between 40 to 50 years. In recent times, the adoption of novel therapies such as substrate replacement therapy and chaperone treatment has also increased rapidly. However, enzyme replacement therapy has been the foremost treatment and holds the major market share and is also expected to retain its position throughout the forecast period. Besides, approval of oral chaperone therapy in the developed countries and the development of gene therapy are expected to contribute to the growth of the market. Also, the emergence of biosimilars is expected to rise during the forecast period due to patent expirations.
Higher prevalence of Fabry’s disease in the US, better healthcare infrastructure, reimbursement plans and adoption of novel therapeutics are said to be favourable for the market growth in the region. Besides, more R&D investment from the major health care companies in the region is considerably aiding market growth. Followed by the US is the European region where the incidence of Fabry’s disease is more. Till 2018, the contribution from the Asia Pacific and the LAMEA region was less. But the changing lifestyle, more genetic mutation and high population are expected to contribute to the market growth in this region.
The market players which contribute chiefly to the market share are Actelion Pharma, Amicus Therapeutics, Arena Pharma, Astellas Pharma, Astrazeneca, Biomarin Pharma, Eli Lilly & Company, ISU Abxis, Lexicon Pharma, Merck & Co, Novo Nordisk, Sangamo Therapeutics, Sanofi Genzyme, Takeda, JCR Pharma, Protalix Biotherapeutics, Idorsia Pharma, Avrobio, Greenovation Biotech, Moderna Therapeutics, Green Cross Pharma and many more…
Request for sample @ https://www.optimainsights.org/sample-request/184-fabry-disease-treatment-market
The present market analytics report on Fabry’s Disease from Optima Insights is a part of the First Series on Rare Metabolic Disorders consisting of a detailed analysis on the epidemiology, products, pipeline drugs, key drivers & restraints, challenges, reimbursement policies on the inherited metabolic disorders that require more attention. Further, every part of the rare metabolic disorder series will cover 10 disorders categorized based on country prevalence and occurrence.
The Fabry’s Disease Market Report is segmented based on Disease Type (Type I, II & III), By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy, and Chaperone Treatment) and By Region (North America, Europe, APAC and LAMEA).
- Provides a detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
- Provides a Comparative Analysis of Key Marketed and Pipeline Products.
- Provides Key Information on Players involved.
- Provides a Complete Overview of Market Segments and the Regional Outlook.
- Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
- History of the Fabry’s Disease Market, 2015 to 2018
- Forecast of the Fabry’s Disease Market Growth till the year 2027
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Fabry’s Disease Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Download Complete TOC of the Report @ https://www.optimainsights.org/reports/184-fabry-disease-treatment-market
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)